RecruitingPHASE1, PHASE2NCT03382977

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Studying Glioblastoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: VBI Vaccines Inc.
Principal Investigator: Francisco Diaz-Mitoma, MD, MD
Variation Biotechnologies Inc.
Intervention: VBI-1901(biological)
Enrollment: 98 enrolled
Eligibility: 18 years · All sexes
Timeline: 2017 – 2025

Study locations (12)

University of California, Irvine, Irvine, California, United States
University of California, San Diego, La Jolla, California, United States
University of California, Los Angeles Neuro-Oncology Program, Los Angeles, California, United States
Stanford, Stanford, California, United States
Miami Cancer Institute, Miami, Florida, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
The Valley Hospital - Neurosurgeons of New Jersey, Ridgewood, New Jersey, United States
The Neurological Institute of New York Columbia University Medical Center, New York, New York, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Providence - Swedish Medical Center, Seattle, Washington, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03382977 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma →

← Back to all trials